lutetium-lu-177-dotatate and Rhabdoid-Tumor

An 18-year-old girl presented with a 3-year history of a recurrent skull base mass confirmed to be a rhabdoid papillary meningioma. The tumor was octreotide avid and metastatic to the lungs, thoracic lymph nodes, and bones, and she was referred for PRRT (peptide receptor radionuclide therapy) with 177Lu DOTATATE. After 3 induction treatment cycles of 177Lu DOTATATE, she experienced significant improvements in her symptoms; however, just before the fourth treatment, she developed cervical spinal cord compression and passed away shortly thereafter. The use of 177Lu DOTATATE therapy in the management of rhabdoid papillary meningioma warrants further research.

Topics: Adolescent; Female; Humans; Meningeal Neoplasms; Meningioma; Octreotide; Organometallic Compounds; Radiopharmaceuticals; Receptors, Peptide; Rhabdoid Tumor